In adrenocortical tumors, the malignant phenotype is associated with rearrangements (paternal isodisomy) at the 11p15 locus and IGF-II gene overexpression, strongly suggesting that the IGF system is a major determinant of adrenocortical tumor progression.
INTRODUCTION
Malignant adrenocortical carcinomas are rare tumors with a poor prognosis. The molecular mechanisms involved in adrenocortical tumorigenesis are still poorly understood. Recent studies have focused on alterations of the insulin-like growth factor (IGF) system associated with these tumors. For instance, there are abnormalities at the 11p15 region, where the IGF-II gene maps, in more than 90% of malignant adrenocortical tumors but in less than 10% of benign tumors (Gicquel et al. 1994 (Gicquel et al. , 1997 . The tumors with these abnormalities exhibit strong overexpression of the IGF-II gene (Ilvesmäki et al. 1993 , Gicquel et al. 1994 and large amounts of IGF-II protein (Boulle et al. 1998) . The type 1 IGF receptor (Weber et al. 1997) and the IGF-binding protein-2 (IGFBP-2) (Boulle et al. 1998) are also specifically overproduced in malignant adrenocortical tumors. These findings strongly implicate the IGF system in adrenocortical tumor progression.
The IGF system comprises several elements. The IGFs, IGF-I and IGF-II, are small polypeptides produced in various tissues and cell cultures. They have endocrine and auto/paracrine modes of action (Jones & Clemmons 1995) . Two structurally different IGF receptors have been described, the type 1 IGF receptor mediating most effects of the IGFs and the IGF-II/mannose-6-phosphate receptor the function of which should be the internalization and subsequent degradation of IGF-II (Jones & Clemmons 1995) . IGF-I and IGF-II can also bind with high affinity to IGFBPs. Six high-affinity IGFBPs have been described to date (Jones & Clemmons 1995) . These IGFBPs modulate the effects of IGFs either positively or negatively depending on their abundance, their affinity for the growth factors and their cellular localization.
IGF-II has been implicated in the growth of various tumors including Wilms' tumors, hepatomas, colon carcinomas and pheochromocytomas, suggesting that IGF-II plays a central role in tumorigenesis (Christofori et al. 1994 , Werner & LeRoith 1996 . Similarly, IGF-II may also be involved in adrenocortical tumors. However, direct proof for this role is lacking. We therefore tested an in vitro adrenocortical tumor model to investigate the autocrine role of IGF-II in the growth of such tumors. We took advantage of a cell line (NCI H295R) established from a human malignant adrenocortical tumor (Gazdar et al. 1990 , Rainey et al. 1994 .
In this paper, we show that the H295R cell line is a suitable in vitro model for studying the role of the IGF system in adrenocortical tumorigenesis and demonstrate that IGF-II is an auto/paracrine factor involved in the proliferation of adrenocortical tumor cells.
MATERIALS AND METHODS

Cell cultures
NCI H295R cells (National Cancer Institute, Bethesda, MD, USA) were grown in a 1:1 mixture of Dulbecco's modified eagle's medium (DMEM) and Ham's F12 medium (Sigma Chemical Company, St Louis, MO, USA) supplemented with transferrin (5 µg/ml; Sigma), sodium selenite (5 ng/ml; Sigma), -glutamine (2·5 mM; Gibco BRL, Paisley, Strathclyde, UK) and antibiotics (50 µg/ml streptomycin, 50 IU/ml penicillin; Gibco BRL) with or without 2% Ultroser G (Biosepra, Marlborough, MA, USA) at 37 C in a 5% CO 2 atmosphere. After reaching confluence, cells were split using 0·05% trypsin with 0·02% EDTA, and they were used at passages three to six for experiments.
For proliferative analyses, cells were grown for up to 26 days in 78 cm 2 dishes (4 10 3 cells/cm 2 ) (Nunc, Roskilde, Denmark) in serum-free medium, which was changed every 48 h. The medium was collected after various times of culture for IGF and IGFBP assays and the cells were counted or treated for RNA extraction.
For antibody experiments, cells were grown in serum-free medium in 96-well dishes (10 5 cells/cm 2 ) (Nunc). After 4 days of culture, the medium was renewed (time 0 of the experiment) and replaced every day with or without the indicated concentrations of monoclonal anti-type 1 IGF receptor antibody (1, 2, 5, 10 and 15 µg/ml) ( IR3; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-IGF-II antibody (1, 2, 5, 10 and 30 µg/ml) (UBI, Lake Placid, NY, USA). Non-specific antibody (mouse IgG1 (MOPC-21); Sigma) was used as a control at the same concentrations as either IR3 or anti-IGF-II antibodies. Cells fed only with serum-free medium were also used as controls. Ninety-six hours after the addition of antibodies, the incorporation of [ 3 H]thymidine was assayed as described below. 
IGF assays
The methods used have been described in detail elsewhere (Hardouin et al. 1989) . Lyophilized samples corresponding to 2·5-12·5 ml culture medium were gel filtered in 1 M acetic acid on columns of Ultrogel AcA 54 (Biosepra) to separate IGFs from IGFBPs. The eluates were lyophilized and, before being assayed, desalted on Sephadex G-25 disposable columns (Pharmacia, Sweden) in assay buffer. IGF-I was assayed by RIA using an anti-IGF-I antibody (gift from Dr J Closset, Liege, Belgium). IGF-II was measured by competitive protein binding assay using IGFBPs extracted from cerebrospinal fluid, which have a selective affinity for IGF-II ).
The IGF preparations used for radiolabeling and as standards were recombinant human IGF-I and IGF-II, kindly provided by Ciba Geigy (Basel, Switzerland).
Steroid assays
Steroid production by H295R cells was measured in conditioned media from cells grown for 48 h in serum-free medium. Progesterone, dehydroepiandrosterone sulfate (DHEA-S), cortisol and aldosterone levels were determined using the 125 I-progesterone Coatria kit (Biomerieux, Lyon, France), the 125 I-DHEA-S kit (Immunotech, Marseille, France), the Gamma Coat 125 I-cortisol kit (Incstar Corp., Stillwater, MN, USA) and the Coat-A-Count 125 I-aldosterone kit (Diagnostic Products Corp., Los Angeles, CA, USA) respectively. Moreover, pregnenolone (PREG), 17-hydroxypregnenolone (17OH-PREG), 17-hydroxyprogesterone (17OH-P), dehydroepiandrosterone (DHEA), delta-4 androstenedione, 11-deoxycorticosterone (DOC), 11-deoxycortisol (11-DOF), corticosterone, 11 -OH delta-4 androstenedione (11 OH-A) and testosterone levels were quantified by specific RIA methods involving chromatographic purification of medium extracts as previously described (Fiet et al. 1994) .
Western ligand and immunoblotting
Western ligand and immunoblotting were performed as previously described (Hossenlopp et al. 1986 , Lalou & Binoux 1993 . Briefly, conditioned media were concentrated by lyophilization, denatured at 100 C for 2 min and subjected to 11% PAGE under non-reducing conditions, and then electrotransferred onto nitrocellulose (BA 85; Schleicher and Schuell, Dassel, Germany). The different IGFBP species were detected by: (i) incubation with a mixture of 125 I-IGF-I and 125 I-IGF-II (5 10 5 c.p.m. each) at 4 C for 48 h, followed by autoradiography (ligand blotting); and (ii) incubation with specific antibodies: anti-human IGFBP-1 serum and anti-human IGFBP-3 serum kindly provided by Dr Binoux (Inserm U 142, Paris, France), anti-bovine IGFBP-2, anti-human IGFBP-4 and anti-human IGFBP-5 polyclonal antibodies purchased from Upstate Biotechnology (Lake Placid, NY, USA). Anti-human IGFBP-6 polyclonal antibody was obtained from A F Schü tzdeller (Tü bingen, Germany). After incubation with a second anti-IgG antibody coupled to horseradish peroxidase (BIO Source, Camarillo, CA, USA), the complexes were visualized by chemiluminescence using the enhanced chemiluminescence Western blotting detection system (Amersham).
For IGF-II immunoblotting, 800 µl conditioned medium (cells cultured for 48 h in serum-free medium) were lyophilized, loaded on a 12·5% non-denaturing gel and transferred to nitrocellulose. The blot was probed with an anti-rat IGF-II monoclonal antibody (1/500) purchased from Upstate Biotechnology. This antibody is specific for rat and human IGF-II and shows less than 10% cross-reactivity with human IGF-I.
Ligand binding assays for IGF cell surface receptors
Cells were plated out in 24-well dishes (5 10 5 cells/cm 2 ) (Nunc) and cultured for 48 h in medium with 2% Ultroser G. The cells were rinsed three times and fed with 1 ml/well fresh serum-free medium. After 24 h, the cell monolayers were placed on ice and washed with 1 ml binding medium (DMEM/F12 (1:1), 25 mM Hepes pH 7·4, 2·5 mM -glutamine, 1 mg/ml BSA (Pasteur Biomérieux, Lyon, France)), preincubated for 30 min with unlabeled ligand and then incubated in a total volume of 0·25 ml binding medium for 4 h at 4 C with 125 I-IGF-I (2·8 10 4 c.p.m.) or 125 I-IGF-II (2·3 10 4 c.p.m.) (7 10 5 c.p.m./pmol IGF-I; 5·3 10 5 c.p.m./pmol IGF-II), with various concentrations of either IGF-I (0·01 nM to 10 µM), IGF-II (0·01 to 1000 nM), des(1-6)IGF-II (GroPep, Adelaide, Australia) (0·01-10 µM) or insulin (Sigma) (0·1 nM to 100 µM). At the end of incubation, cells were washed four times with Hanks' solution (Sanofi Pasteur, Marnes la coquette, France) at 4 C and then lysed at room temperature in 0·5 M NaOH. Cell-associated radioactivity was counted in a gamma counter.
Isolation of RNA and mRNA analysis
Total RNA was isolated as previously described (Chomczynski & Sacchi 1987) . Briefly, cells were rinsed three times in PBS, lysed in 4 M guanidinium thiocyanate, 25 mM sodium citrate pH 7, 0·5% sarkosyl and 0·1 M -mercaptoethanol and RNA was extracted by the phenol-chloroform method. Seven micrograms of total RNA were loaded onto a 1·1% agarose-formaldehyde gel, then transferred to a Genescreen plus membrane (NEN Research Products, DuPont de Nemours & Co., Germany), and covalently bound to the membrane by UV irradiation. Northern blots were hybridized with cDNA probes for human IGF-II (Le Bouc et al. 1987 ), IGFBP-2 or IGFBP-3 (kindly provided by Dr Binoux, Inserm U 142, Paris, France).
Type 1 and type 2 IGF receptors expression was analyzed by reverse transcription PCR (RT-PCR). RNA samples (1 µg) were treated with DNase to eliminate any DNA contamination, reversetranscribed using Moloney murine leukemia virus reverse transcriptase (Gibco) and resulting cDNA amplified by PCR. Sense and antisense primers for the type 1 IGF receptor were respectively 5 AAC CAC GAG GCT GAG AAG CT and 5 CAG CAT AAT CAC CAA CCC TC (Ilvesmäki et al. 1993) . Oligonucleotide primers to type 2 IGF receptor were designed within the 3 UTR of the human IGF-II receptor (Hol et al. 1992) . Sense and antisense primers were respectively 5 TTG CCG GCT GGT GAA TTC AA and 5 GTA TCA TGA GAA CCT GAA GAG. DNase-treated RNA PCR products were used as control for DNA contamination of the RNA samples. Products of amplification were analyzed by electrophoresis on a 1·5% agarose gel. Gazdar et al. (1990) established the H295 cell line from an invasive primary adrenocortical carcinoma. This cell line was the first to maintain the ability to produce all the adrenocortical steroids. Later, Rainey et al. (1994) selected a population of H295 cells with anchorage-dependent growth which they named the NCI H295R cell line. These adherent cells were used for the present study.
RESULTS
H295R cells grow spontaneously in serum-free medium
Preliminary studies with H295 cells showed that they had a long population doubling time (>96 h) and could only proliferate in medium supplemented with selenium, insulin and transferrin (Gazdar et al. 1990 , Rainey et al. 1994 ). Because we wanted to study the role of the IGF system in H295R cell proliferation, it was important to verify the spontaneous growth of this cell line in the absence of any added growth factors, particularly insulin, which could interfere with the type 1 IGF receptor.
H295R cells were capable of spontaneous although slow growth in the absence of serum or added growth factors (Fig. 1) . In the exponential phase, the number of cells doubled every 2·5 days after a 15 day latency period.
We also extensively studied the secretion of steroids by H295R cells growing in serum-free medium (Fig. 2) . H295R cells were pluripotent cells and produced glucocorticoids, mineralocorticoids and androgens. The production of androgens was predominant, involving mainly the delta-4 pathway (i.e. progesterone, 17OH-P, androstenedione) when the delta-5 pathway was minor (i.e. PREG, 17OH-PREG, DHEA). High levels of DOC and 11-DOF and lower levels of corticosterone, cortisol and 11 OH-A suggested a potential alteration in the 11 -hydroxylase activity.
IGF-II is produced by H295R cells
We previously showed high IGF-II mRNA and protein contents in malignant adrenocortical tumors (Gicquel et al. 1994 , Boulle et al. 1998 . Such IGF-II production would be expected from the H295R cell line as it was derived from a malignant human adrenocortical tumor. IGF-I and IGF-II proteins were measured in conditioned media from these cells cultured in serum-free medium (Fig.  3A) . H295R cells secreted large amounts of IGF-II protein and the amount of growth factor produced per cell increased with time in culture (from 14 ng/10 6 cells per 48 h at day 2 to 72 ng/10 6 cells per 48 h at day 11). By contrast, IGF-I protein was not detected in conditioned media. The IGF-II assay used here allowed measurement of mature 7·5 kDa IGF-II ). To determine whether other forms of the growth factor were produced by H295R cells, aliquots of conditioned media were immunoblotted with a specific IGF-II antibody (Fig. 3B) . Both the mature 7·5 kDa peptide and significant amounts of high molecular weight forms of IGF-II (from 8·5 to 24 kDa), presumably precursor forms, were detected.
Northern blotting analysis showed that the sizes of IGF-II mRNA (2·2, 4·8 and 6·0 kb) were the same as in normal adrenal tissues and tumors ( Fig. 3C) (Gicquel et al. 1994) . Kinetic analysis of IGF-II gene expression showed an increase in IGF-II mRNA during proliferation in serum-free medium (Fig. 3C) .
IGFBPs secretion by H295R cells
IGFBPs are important regulators of IGF effects. We therefore examined the production of IGFBPs by H295R cells. Western ligand blotting detected a major band of 34 kDa in the culture medium of H295R cells that co-migrated with the 34 kDa band of a control human serum (Fig. 4A ). After prolonged cell proliferation (18-20 days), a minor 39-42 kDa doublet was also detected (Fig. 4A) . Immunoblotting, using specific antisera, identified the 34 kDa band as IGFBP-2 (Fig. 4A ) and the 39-42 kDa doublet as IGFBP-3 (Fig. 4B) . In both cases, the IGFBP appeared as an intact protein by comparison with a control human serum and no proteolytic fragments were detected either with anti-IGFBP-2 or anti-IGFBP-3 antibodies. Specific antisera to IGFBP-1, -4, -5 and -6 failed to identify these IGFBPs in H295R-conditioned medium (data not shown). In agreement with the ligand blot data, Northern blot analyses showed that H295R cells contained mRNAs for IGFBP-2 (1·6 kb) and IGFBP-3 (2·6 kb) (Fig. 4C) .
Binding of 125 I-IGF-I and 125 I-IGF-II to H295R cells
The next series of experiments investigated the existence of IGF binding sites on H295R cell surface. IGF-I binding is shown in Fig. 5A . The mean specific binding of 125 I-IGF-I to H295R cells was 12·3 0·3% (...) and it was effectively displaced by unlabeled IGF-I with a 50% displacement (IC 50 ) at 0·53 nmol/l. IGF-II and insulin competitively inhibited the binding of 125 I-IGF-I in a decreasing order according to their affinity to the type 1 IGF receptor (5-fold and 1500-fold lower affinities for respectively IGF-II and insulin). Fig. 5B . The mean specific binding of 125 I-IGF-II to H295R cells was 12·8 0·4% and it was effectively displaced by unlabeled IGF-II with an IC 50 of 1·7 nmol/l. Partial displacement of 125 I-IGF-II was possible with IGF-I and insulin, confirming the presence of the type 1 IGF receptor. However, this displacement of 125 I-IGF-II from the H295R cell surface by IGF-I and insulin was not complete, suggesting that these cells also express a specific IGF-II binding site different from the type 1 IGF receptor. The complete displacement of 125 I-IGF-II by des(1-6)IGF-II excludes an IGFBP as the second IGF-II binding site and rather suggests that this site is the type 2 IGF receptor.
IGF-II binding is shown in
The presence of type 1 and type 2 IGF receptors on H295R cells was confirmed by RT-PCR analyses showing that both receptors are expressed by this cell line (Fig. 6 ).
IGF-II is involved in proliferation of H295R cells through the type 1 IGF receptor
The high levels of IGF-II expression and the presence of IGF-II binding sites on H295R cells are strong evidence for an autocrine role of IGF-II in H295R cell growth. To confirm this, [
3 H]thymidine incorporation as a measure of H295R cell proliferation was studied in the presence of an anti-IGF-II  2. Steroid production by H295R cells cultured in serum-free medium, as determined by RIA. Steroid levels are expressed in nmol/10 6 cells per 48 h. A=androstenedione, ALDO=aldosterone, B=corticosterone, F=cortisol, P=progesterone, T=testosterone, HSD=hydroxy-steroid dehydrogenase.
antibody that specifically neutralizes IGF-II, and in the presence of the IR3 antibody which blocks the type 1 IGF receptor. Dose-response curves for the effects of anti-IGF-II and IR3 antibodies on [ 3 H]thymidine incorporation are shown in Fig. 7 .
Both the anti-IGF-II antibody and the IR3 antibody inhibited H295R cell proliferation in a dose-dependent manner with maximal inhibitions of 45 and 53·4% respectively, compared with control cells (Fig. 7) . This effect was specific and normal mouse IgG (1-30 µg/ml) had no effect on cell proliferation when compared with cells fed only with serum-free medium (data not shown). These results are direct evidence that IGF-II, acting, at least in part, through the type 1 receptor, is involved in the autocrine proliferation of H295R cells.
DISCUSSION
There is increasing evidence that IGF-II plays a determinant role in tumor proliferation (reviewed in Werner & LeRoith 1996) . This is particularly true for adrenocortical tumors. Study of the IGF system in these tumors indeed showed that strong overexpression of the IGF-II gene is a frequent feature of the malignant state (Ilvesmäki et al. 1993 , Gicquel et al. 1994 , Liu et al. 1995 . The IGF-II gene IGF-II immunoblotting. Conditioned medium from cells cultured for 48 h in serum-free medium (800 µl) was lyophilized and loaded on a 12·5% polyacrylamide gel, then analyzed by immunoblotting, using a specific anti-IGF-II monoclonal antibody. IGF-II (100 ng) and protein extracts (250 µg) from malignant adrenocortical (AC) and hypoglycemic tumors were used as controls. (C) Northern blot analysis of IGF-II gene expression. The 6·0 kb and 2·2 kb mRNA species are transcribed from the P3 promoter and the 4·8 kb mRNA species from the P4 promoter. maps to the 11p15 imprinted region and is expressed from the paternal allele (De Chiara et al. 1991 , Ogawa et al. 1993 , Rainier et al. 1993 . The mechanism of IGF-II gene overexpression in malignant tumors involves pathological imprinting. Indeed, most tumors with overexpression of the IGF-II gene also exhibit paternal isodisomy (loss of the maternalderived allele and duplication of the IGF-II active paternal allele) or, less frequently, loss of imprinting (with maintenance of the maternal allele but a paternal-like IGF-II gene expression pattern) (Gicquel et al. 1997) . IGF-II mRNA is efficiently translated and malignant tumors contain large amounts of IGF-II protein, partly as precursor forms (Boulle et al. 1998) . IGF-I and IGF-II receptors are present in adrenal tissues and overexpression of the type 1 IGF receptor has been shown in adrenocortical carcinomas (Kamio et al. 1991 , Ilvesmäki et al. 1993 , Backlin et al. 1995 , Weber et al. 1997 . These previous studies all used frozen tumor tissues and give strong evidence for a role for IGF-II in adrenocortical tumor proliferation. However, no direct proof of the contribution of IGF-II is available. To investigate the function of IGF-II in growth regulation of adrenocortical tumors, we used the H295R cell line (Rainey et al. 1994) derived from the H295 cell line established from an invasive hormonally active primary adrenocortical carcinoma ( Gazdar et al. 1990) . Analysis of the IGF system of this cell line has not been described other than some preliminary results on IGF-II mRNA production (Staels et al. 1993) .
H295R cells spontaneously grow in serum-free medium suggesting that they may secrete autocrine growth factors. Here we show that the IGF-II (and not the IGF-I) gene is strongly expressed in H295R cells as in malignant human adrenocortical tumors (Ilvesmäki et al. 1993 , Gicquel et al. 1994 . We also show that IGF-II mRNAs are efficiently translated, with accumulation of IGF-II protein in culture media during cell proliferation, partly as precursor forms, as we previously showed in frozen adrenocortical carcinomas (Boulle et al. 1998 (Weber et al. 1997 ) but the expression of the IGF-II M6P receptor in adrenocortical tumors has only been studied at the mRNA level; RT-PCR has been used to show that the gene is expressed both in normal and tumorous adrenals (Ilvesmäki et al. 1993) .
IGFBP-2 has a 10-fold higher affinity for IGF-II than for IGF-I and is the IGFBP most frequently produced by malignant tumor cells (Reeve et al. 1992) . Whether IGFBP-2 has an inhibitory or stimulatory effect on H295R cell proliferation remains to be demonstrated. Recently several indirect arguments indicate that IGFBP-2 may potentiate IGF action by focally concentrating the IGFs in the pericellular environment , Arai et al. 1996 , Russo et al. 1997 ) but the precise mechanism is still unknown. In the case of adrenocortical tumor cells, which are highly proliferative, IGFBP-2 may possibly have a As stated above, malignant adrenocortical tumors frequently display imprinting abnormalities of the 11p15 region. Whether this occurred in the primitive adrenocortical tumor from which the H295R cell line is derived is not known. However, we found that the expression of two genes, both normally expressed from the maternal allele, H19 and p57 KIP2 , was abrogated (data not shown) suggesting that H295R cells share abnormalities of 11p15 imprinting with malignant adrenocortical tumors.
In conclusion, our observations show that the H295R cell line is a good model of adrenocortical tumorigenesis; the cells maintain steroid production (particularly androgen production) and, produce, like human malignant tumors, high amounts of IGF-II and IGFBP-2. We also demonstrate that IGF-II is directly involved in tumor proliferation and that its effects are mediated, at least in part, by the type 1 IGF receptor in an autocrine fashion.
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